Evidence map›Paper›PMID 33711293›Full record

ArticleThe Lancet. Child & adolescent health2021

Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study.

Joseph Y Abrams, Matthew E Oster, Shana E Godfred-Cato, Bobbi Bryant, S Deblina Datta, Angela P Campbell, Jessica W Leung, Clarisse A Tsang, Timmy J Pierce, Jordan L Kennedy and 2 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Lancet. Child & adolescent health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07659847 (Cardiovascular Evaluation 5 Years After Multisystem Inflammatory Syndrome in Children), which is not on this map. Cited by 175 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 8 pooled it
64.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07659847 recruitingnot on this mapstarted 2025, after this paper: background citation

Cardiovascular Evaluation 5 Years After Multisystem Inflammatory Syndrome in Children (MIS-C)

TypeobservationalSponsorMedical University of WarsawRan2025 to 2027Enrolled90ConditionsMultisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 8 syntheses or guidelines pooled it, 341 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026
    Review
  17. Article
  18. Article
  19. Article
  20. Article

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Joseph Y AbramsCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: jabrams@cdc.gov.
Matthew E OsterCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Shana E Godfred-CatoCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Bobbi BryantCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA; Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
S Deblina DattaCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Angela P CampbellCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jessica W LeungCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Clarisse A TsangCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Timmy J PierceCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jordan L KennedyCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Teresa A HammettCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ermias D BelayCDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Centers for Disease Control and Prevention · USOak Ridge Associated Universities · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultisystem inflammatory syndrome in children (MIS-C) is a newly identified and serious health condition associated with SARS-CoV-2 infection. Clinical manifestations vary widely among patients with MIS-C, and the aim of this study was to investigate factors associated with severe outcomes.

methodsIn this retrospective surveillance study, patients who met the US Centers for Disease Control and Prevention (CDC) case definition for MIS-C (younger than 21 years, fever, laboratory evidence of inflammation, admitted to hospital, multisystem [≥2] organ involvement [cardiac, renal, respiratory, haematological, gastrointestinal, dermatological, or neurological], no alternative plausible diagnosis, and either laboratory confirmation of SARS-CoV-2 infection by RT-PCR, serology, or antigen test, or known COVID-19 exposure within 4 weeks before symptom onset) were reported from state and local health departments to the CDC using standard case-report forms. Factors assessed for potential links to severe outcomes included pre-existing patient factors (sex, age, race or ethnicity, obesity, and MIS-C symptom onset date before June 1, 2020) and clinical findings (signs or symptoms and laboratory markers). Logistic regression models, adjusted for all pre-existing factors, were used to estimate odds ratios between potential explanatory factors and the following outcomes: intensive care unit (ICU) admission, shock, decreased cardiac function, myocarditis, and coronary artery abnormalities.

findings1080 patients met the CDC case definition for MIS-C and had symptom onset between March 11 and Oct 10, 2020. ICU admission was more likely in patients aged 6-12 years (adjusted odds ratio 1·9 [95% CI 1·4-2·6) and patients aged 13-20 years (2·6 [1·8-3·8]), compared with patients aged 0-5 years, and more likely in non-Hispanic Black patients, compared with non-Hispanic White patients (1·6 [1·0-2·4]). ICU admission was more likely for patients with shortness of breath (1·9 [1·2-2·9]), abdominal pain (1·7 [1·2-2·7]), and patients with increased concentrations of C-reactive protein, troponin, ferritin, D-dimer, brain natriuretic peptide (BNP), N-terminal pro B-type BNP, or interleukin-6, or reduced platelet or lymphocyte counts. We found similar associations for decreased cardiac function, shock, and myocarditis. Coronary artery abnormalities were more common in male patients (1·5 [1·1-2·1]) than in female patients and patients with mucocutaneous lesions (2·2 [1·3-3·5]) or conjunctival injection (2·3 [1·4-3·7]).

interpretationIdentification of important demographic and clinical characteristics could aid in early recognition and prompt management of severe outcomes for patients with MIS-C.

fundingNone.

Indexed as

AdolescentBiomarkersChildChild, PreschoolCOVID-19Critical CareEarly DiagnosisEthnicityFemaleHumansInfantInfant, NewbornMaleRetrospective StudiesRisk FactorsSystemic Inflammatory Response SyndromeBiomarkers

Identifiers

PMID33711293
PMCPMC7943393
OpenAlexW3135665874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.